Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)

Published:2024-02 Issue: Volume:188 Page:107455
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Cheng Ying^ORCID,Wu Lin,Huang Dingzhi,Wang QiMing,Fan Yun,Zhang XiQin,Fan HuiJie,Yao WenXiu,Liu BaoGang,Yu GuoHua,Pan YueYin,Xu Fei,He ZhiYong,Dong XiaoRong,Ma Rui,Min XuHong,Ge XiaoSong,Chen Hualin,Liu Qun,Hu YanPing,Liu Ying,Yang Chen,Yang Yang,Li Xiucui,Zhou Li

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference23 articles.

1. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study;Zheng;Cancer Manag. Res.,2022

2. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion;Das;Adv. Ther.,2021

3. Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers;Epstein;J. Med. Econ.,2022

4. Drug-Induced Myelosuppression: Diagnosis and Management;Carey;Drug-Safety,2003

5. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice;Bryer;IJCTM,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP